Log in

Relevant bibliographies by topics / III colorectal cancer / Journal articles

To see the other types of publications on this topic, follow the link: III colorectal cancer.

Journal articles on the topic 'III colorectal cancer'

Author: Grafiati

Published: 4 June 2021

Last updated: 14 February 2022

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic 'III colorectal cancer.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Wang, Ning, Yang Chen, Yuchen Han, et al. "Proteomic analysis shows down-regulations of cytoplasmic carbonic anhydrases, CAI and CAII, are early events of colorectal carcinogenesis but are not correlated with lymph node metastasis." Tumori Journal 98, no. 6 (2012): 783–91. http://dx.doi.org/10.1177/030089161209800617.

Full text

Abstract:

Aim The aim of the study was to screen the markedly down-regulated proteins in colorectal cancer and analyze their relationship to carcinogenesis, cancer progression and pathological aspects. Methods Proteomic analysis was preformed on six fresh colorectal cancer tissues and paired normal colorectal mucosa by two-dimensional differential gel electrophoresis and matrix-assisted laser desorption/ionization-time of flight mass spectrometry. Two markedly down-regulated proteins among the proteins, of which the expressions were significantly decreased in colorectal cancer compared to normal mucosa,

APA, Harvard, Vancouver, ISO, and other styles

2

Compton, Carolyn C., L. Peter Fielding, Lawrence J. Burgart, et al. "Prognostic Factors in Colorectal Cancer." Archives of Pathology & Laboratory Medicine 124, no. 7 (2000): 979–94. http://dx.doi.org/10.5858/2000-124-0979-pficc.

Full text

Abstract:

Abstract Background.—Under the auspices of the College of American Pathologists, the current state of knowledge regarding pathologic prognostic factors (factors linked to outcome) and predictive factors (factors predicting response to therapy) in colorectal carcinoma was evaluated. A multidisciplinary group of clinical (including the disciplines of medical oncology, surgical oncology, and radiation oncology), pathologic, and statistical experts in colorectal cancer reviewed all relevant medical literature and stratified the reported prognostic factors into categories that reflected the strengt

APA, Harvard, Vancouver, ISO, and other styles

3

Li, Chenglong, Qian Pei, Hong Zhu, et al. "Survival nomograms for stage III colorectal cancer." Medicine 97, no. 49 (2018): e13239. http://dx.doi.org/10.1097/md.0000000000013239.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

Malatay González, Carlos Humberto, Juan Bernardo Pazmiño Palacios, Luis Andrés Idrovo Murillo, Jhónatan Miguel Siguencia Muñoz, and Adriana Ximena Bravo Andrade. "Experiencia Quirúrgica en el Manejo del Cáncer de Recto. Hospital de SOLCA, Guayaquil – Ecuador." Revista Médica del Hospital José Carrasco Arteaga 12, no. 2 (2020): 92–97. http://dx.doi.org/10.14410/2020.12.2.ao.13.

Full text

Abstract:

BACKGROUND: Colorectal cancer is the third most common among malignant neoplasms worldwide. Treatment choice depends on the location of the tumor, among other factors, and varies from local excision to abdominoperineal resection, adjuvant or neoadjuvant therapy can be needed, depending on clinical stage. The purpose of this study was to determine the most common histological type of rectal cancer, establish the most frequent clinical stage at diagnosis, the most common surgical technique and complications. METHODOLOGY: A cross-sectional study was carried out, with 160 patients treated in the d

APA, Harvard, Vancouver, ISO, and other styles

5

Wang, Yuwei, Yadong Long, Ye Xu, et al. "Prognostic and Predictive Value of CpG Island Methylator Phenotype in Patients with Locally Advanced Nonmetastatic Sporadic Colorectal Cancer." Gastroenterology Research and Practice 2014 (2014): 1–7. http://dx.doi.org/10.1155/2014/436985.

Full text

Abstract:

Purpose. In the present study, the prognostic significance of CpG island methylator phenotype (CIMP) in stage II/III sporadic colorectal cancer was evaluated using a five-gene panel.Methods. Fifty stage II/III colorectal cancer patients who received radical resection were included in this study. Promoter methylation of p14ARF, hMLH1, p16INK4a, MGMT, and MINT1 was determined by methylation specific polymerase chain reaction (MSP). CIMP positive was defined as hypermethylation of three or more of the five genes. Impact factors on disease-free survival (DFS) and overall survival (OS) were analyze

APA, Harvard, Vancouver, ISO, and other styles

6

Takashima, Atsuo, Kenichi Miyamoto, Yuya Sato, et al. "Efficacy of aspirin for stage III colorectal cancer: A randomized double-blind placebo-controlled trial (JCOG1503C, EPISODE-III trial)." Journal of Clinical Oncology 37, no. 15_suppl (2019): TPS3623. http://dx.doi.org/10.1200/jco.2019.37.15_suppl.tps3623.

Full text

Abstract:

TPS3623 Background: Adjuvant chemotherapy is the current standard treatment for stage III colorectal cancer after curative resection. However, the prognosis of stage III colorectal cancer is still poor even after curative resection and adjuvant chemotherapy. Recently, several observational studies suggested the anti-tumor effect of aspirin for advanced colorectal cancer. The main mechanism of the anti-tumor effect by aspirin may be to suppress cyclooxygenase activity in the arachidonic acid cascade and to inhibit the production of prostaglandins involved in tumor growth. So far, aspirin showed

APA, Harvard, Vancouver, ISO, and other styles

7

Li, Tao, Guoliang Liu, Jiannan Li, et al. "Gastric tumorigenesis after radical resection combined with adjuvant chemotherapy for colorectal cancer: two case reports and a literature review." Journal of International Medical Research 49, no. 4 (2021): 030006052110070. http://dx.doi.org/10.1177/03000605211007050.

Full text

Abstract:

Radical resection with or without adjuvant chemotherapy is a common option for stage II and III colorectal cancer. Few reports exist regarding gastric tumorigenesis, including gastric cancer, gastric intraepithelial neoplasia, and gastric stromal tumor, in patients who received this protocol as the standard treatment for colorectal cancer. We present two cases of gastric tumorigenesis in patients with colorectal cancer following radical resection combined with adjuvant chemotherapy. Both patients underwent gastrectomy and D2 lymphadenectomy for their gastric tumors; neither patient developed r

APA, Harvard, Vancouver, ISO, and other styles

8

Anuraga, Gangga, Wan-Chun Tang, Nam Phan, et al. "Comprehensive Analysis of Prognostic and Genetic Signatures for General Transcription Factor III (GTF3) in Clinical Colorectal Cancer Patients Using Bioinformatics Approaches." Current Issues in Molecular Biology 43, no. 1 (2021): 2–20. http://dx.doi.org/10.3390/cimb43010002.

Full text

Abstract:

Colorectal cancer (CRC) has the fourth-highest incidence of all cancer types, and its incidence has steadily increased in the last decade. The general transcription factor III (GTF3) family, comprising GTF3A, GTF3B, GTF3C1, and GTFC2, were stated to be linked with the expansion of different types of cancers; however, their messenger (m)RNA expressions and prognostic values in colorectal cancer need to be further investigated. To study the transcriptomic expression levels of GTF3 gene members in colorectal cancer in both cancerous tissues and cell lines, we first performed high-throughput scree

APA, Harvard, Vancouver, ISO, and other styles

9

Schindler, Isabell, Patricia Grabowski, Iannis Anagnostopoulos, et al. "Neuroendocrine differentiation in stage III–IV colorectal cancer." Gastroenterology 118, no. 4 (2000): A511. http://dx.doi.org/10.1016/s0016-5085(00)84170-0.

Full text

APA, Harvard, Vancouver, ISO, and other styles

10

Tuma, Rabiya S. "Brivanib Fails in Phase III Colorectal Cancer Trial." Oncology Times 34, no. 4 (2012): 28–29. http://dx.doi.org/10.1097/01.cot.0000413013.92927.c5.

Full text

APA, Harvard, Vancouver, ISO, and other styles

11

Milašienė, Vida, Eugenijus Stratilatovas, and Violeta Norkienė. "The importance of T-lymphocyte subsets on overall survival of colorectal and gastric cancer patients." Medicina 43, no. 7 (2007): 548. http://dx.doi.org/10.3390/medicina43070069.

Full text

Abstract:

The aim of this study was to evaluate the influence of cellular immunity parameters on overall survival of colorectal and gastric cancer patients after surgery. The parameters of cellular immunity (CD3+, CD4+, CD8+, CD20+, and CD16+) were determined by immunofluorescence method. Cox regression analysis showed no impact of the estimated preoperative and postoperative parameters of cellular immunity on overall survival of colorectal cancer patients and similarly of gastric cancer patients in stage II. However, the analysis showed that the survival of colorectal and gastric cancer patients in sta

APA, Harvard, Vancouver, ISO, and other styles

12

Nwe, Khin Khin. "Colorectal cancer in young population: Yangon, Myanmar." Journal of Clinical Oncology 30, no. 15_suppl (2012): e14055-e14055. http://dx.doi.org/10.1200/jco.2012.30.15_suppl.e14055.

Full text

Abstract:

e14055 Background: CRC is the tenth most common cause of cancer in 2006 Myanmar Cancer Statistic. Recently, increased incidence of CRC among young age has been seen in our population. Methods: Demographic data of CRC pts registered in medical oncology unit, YGH from January 2009 to September, 2011 were studied. Age under 40 yrs was considered as a young patient. Stage distribution were analyzed to study about young onset CRC pattern. Results: Among 351 CRC patients registered, 120pts (34.19%) were under 40 yrs old. In young age group, age range from 12 to 40 yrs (median 29.5 yrs). Male to fema

APA, Harvard, Vancouver, ISO, and other styles

13

Lièvre, Astrid, Caroline Chapusot, Anne-Marie Bouvier, et al. "Clinical Value of Mitochondrial Mutations in Colorectal Cancer." Journal of Clinical Oncology 23, no. 15 (2005): 3517–25. http://dx.doi.org/10.1200/jco.2005.07.044.

Full text

Abstract:

Purpose Prognostic factors that could select high-risk recurrence colorectal cancer patients and predict chemosensitivity are needed. Since mutations of mitochondrial DNA (mtDNA) have been described in different types of cancers and since they may play a role in response to anticancer agents, we investigated in a population-based series of colorectal cancer patients the clinical value of mtDNA mutations. Patients and Methods The displacement loop (D-loop) region of mtDNA was sequenced on a series of 365 patients recorded in the Digestive Cancer Registry of Côte-d'Or (France) between 1998 and 2

APA, Harvard, Vancouver, ISO, and other styles

14

Derwinger, Kristoffer, and Bengt Gustavsson. "A study of Aspects on Gender and Prognosis in Synchronous Colorectal Cancer." Clinical Medicine Insights: Oncology 5 (January 2011): CMO.S7871. http://dx.doi.org/10.4137/cmo.s7871.

Full text

Abstract:

Aim To assess differences in demography, pathology and prognosis with tumor multiplicity in colorectal cancer. Method A retrospective single centre study of all patients surgically treated for a colorectal cancer during 1999–2008 (n = 2524). Patient characteristics, pathology and follow-up data were retrieved. Survival was assessed by overall and cancer specific survival. Results 60 (2.4%) patients had a synchronous cancer (SC), associated with right colon, higher age, more assessed lymph nodes but a lower frequency of stage III/IV disease (42% vs. 52%). There was no overall prognostic differe

APA, Harvard, Vancouver, ISO, and other styles

15

Miyamoto, Kenichi, Atsuo Takashima, Junki Mizusawa, et al. "Efficacy of aspirin for stage III colorectal cancer: a randomized double-blind placebo-controlled trial (JCOG1503C, EPISODE-III trial)." Japanese Journal of Clinical Oncology 49, no. 10 (2019): 985–90. http://dx.doi.org/10.1093/jjco/hyz106.

Full text

Abstract:

Abstract Adjuvant chemotherapy is the current standard treatment for stage III colorectal cancer after curative resection. However, the prognosis of stage III colorectal cancer is still poor even after curative resection and adjuvant chemotherapy. Several observational studies suggested that the anti-tumor effect of aspirin. Therefore, we planned a randomized double-blind placebo-controlled phase III trial, which commenced in Japan in March 2018, to confirm the superiority of aspirin over placebo added to adjuvant chemotherapy in terms of disease-free survival (DFS) for stage III colorectal ca

APA, Harvard, Vancouver, ISO, and other styles

16

Kawakatsu, Yukino, Yuriko N. Koyanagi, Isao Oze, et al. "Association between Socioeconomic Status and Digestive Tract Cancers: A Case-Control Study." Cancers 12, no. 11 (2020): 3258. http://dx.doi.org/10.3390/cancers12113258.

Full text

Abstract:

Although socioeconomic status (SES) has been associated with cancer risk, little research on this association has been done in Japan. To evaluate the association between SES and digestive tract cancer risk, we conducted a case-control study for head and neck, esophageal, stomach, and colorectal cancers in 3188 cases and the same number of age- and sex-matched controls within the framework of the Hospital-based Epidemiological Research Program at Aichi Cancer Center III (HERPACC III). We employed the education level and areal deprivation index (ADI) as SES indicators. The association was evalua

APA, Harvard, Vancouver, ISO, and other styles

17

McCleary, Nadine Jackson, Al B. Benson, and Rodrigo Dienstmann. "Personalizing Adjuvant Therapy for Stage II/III Colorectal Cancer." American Society of Clinical Oncology Educational Book, no. 37 (May 2017): 232–45. http://dx.doi.org/10.1200/edbk_175660.

Full text

Abstract:

This review focuses on three areas of interest with respect to the treatment of stage II and III colon and rectal cancer, including (1) tailoring adjuvant therapy for the geriatric population, (2) the controversy as to the optimal adjuvant therapy strategy for patients with locoregional rectal cancer and for patients with colorectal resectable metastatic disease, and (3) discussion of the microenvironment, molecular profiling, and the future of adjuvant therapy. It has become evident that age is the strongest predictive factor for receipt of adjuvant chemotherapy, duration of treatment, and ri

APA, Harvard, Vancouver, ISO, and other styles

18

Wang, Tzu-Fei, and Albert Craig Lockhart. "Aflibercept in the Treatment of Metastatic Colorectal Cancer." Clinical Medicine Insights: Oncology 6 (January 2012): CMO.S7432. http://dx.doi.org/10.4137/cmo.s7432.

Full text

Abstract:

Colorectal cancer is the third most common cancer in the US. In recent decades, an improved understanding of the role of the angiogenesis pathway in colorectal cancer has led to advancements in treatment. Bevacizumab has been shown to improve the progression-free survival and overall survival when combined with cytotoxic chemotherapy in patients with metastatic colorectal cancer, and at present is the only antiangiogenesis agent approved for the treatment of this cancer. Aflibercept is a novel angiogenesis-targeting agent, and has demonstrated efficacy in treating metastatic colorectal cancer

APA, Harvard, Vancouver, ISO, and other styles

19

Lindskog, Elinor B., Yvonne Wettergren, Elisabeth Odin, Bengt Gustavsson, and Kristoffer Derwinger. "Thymidine Phosphorylase Gene Expression in Stage III Colorectal Cancer." Clinical Medicine Insights: Oncology 6 (January 2012): CMO.S10226. http://dx.doi.org/10.4137/cmo.s10226.

Full text

Abstract:

Background The thymidine phosphorylase (TP) enzyme has several tumor-promoting functions. The aim of this study was to explore TP gene expression in relation to clinical and histopathological data obtained from patients with stage III colorectal cancer. Methods and Results TP gene expression was analyzed by real-time quantitative PCR in tumor and mucosa samples from 254 patients. TP gene expression in tumors correlated with lymph node staging, with higher expression relating to a higher number of positive nodes and a worse N-stage. Higher TP expression was also associated with a worse histolog

APA, Harvard, Vancouver, ISO, and other styles

20

Meyerhardt, Jeffrey A., Edward L. Giovannucci, Michelle D. Holmes, et al. "Physical Activity and Survival After Colorectal Cancer Diagnosis." Journal of Clinical Oncology 24, no. 22 (2006): 3527–34. http://dx.doi.org/10.1200/jco.2006.06.0855.

Full text

Abstract:

Purpose Physically active individuals have a lower risk of developing colorectal cancer but the influence of exercise on cancer survival is unknown. Patients and Methods By a prospective, observational study of 573 women with stage I to III colorectal cancer, we studied colorectal cancer–specific and overall mortality according to predefined physical activity categories before and after diagnosis and by change in activity after diagnosis. To minimize bias by occult recurrences, we excluded women who died within 6 months of their postdiagnosis physical activity assessment. Results Increasing le

APA, Harvard, Vancouver, ISO, and other styles

21

Stabuc, Borut. "Systemic therapy for colorectal cancer." Archive of Oncology 11, no. 4 (2003): 255–63. http://dx.doi.org/10.2298/aoo0304255s.

Full text

Abstract:

Colorectal cancer alone accounts for around 200,000 deaths in Europe and represents a significant health problem. Although about fifty percent of patients are cured by surgery alone, the other half will eventually die due to metastatic disease, which includes approximately 25% of patients who have evidence of metastases at the time of diagnosis. Surgical resection of the primary tumor and regional lymph nodes is the only curative therapy for colorectal cancer. However, adjuvant chemotherapy in stage III for colon cancer following curative resection has been shown to reduce the risk of recurren

APA, Harvard, Vancouver, ISO, and other styles

22

Llopis Cuquerella, Marta, Maria del Carmen Ors Castaño, María Ballester Espinosa, et al. "Adjuvant treatment in extreme elderly patients with colorectal cancer." Journal of Clinical Oncology 35, no. 4_suppl (2017): 784. http://dx.doi.org/10.1200/jco.2017.35.4_suppl.784.

Full text

Abstract:

784 Background: Surgical and adjuvant treatment in extreme elderly ( > 80 years) patients with localized colorectal cancer is an unresolved issue. Owing to the lack of available neither clinical practice nor investigational data in this field we present our experience in this scenario. Methods: We retrospectively reviewed data regarding surgical and complementary treatment for colorectal cancer patients aged more than 80 consecutively attended by General Surgery Department in Vega Baja Hospital between 2008 and 2013. Results: A total number of 115 colorectal cancer patients were registered.

APA, Harvard, Vancouver, ISO, and other styles

23

Ueno, Hideki, Hidetaka Mochizuki, Yoshito Akagi, et al. "Optimal Colorectal Cancer Staging Criteria in TNM Classification." Journal of Clinical Oncology 30, no. 13 (2012): 1519–26. http://dx.doi.org/10.1200/jco.2011.39.4692.

Full text

Abstract:

Purpose Histologic components of the TNM classification system have been repeatedly revised since the fifth edition (TNM5). TNM classification revisions provide different criteria for categorizing tumor nodules without residual lymph node structure (ND). However, there are few systematic evaluations regarding the effectiveness of these revisions. Patients and Methods A multicenter pathologic review for ND in colorectal cancer (CRC) was performed. Tumor staging defined by TNM5, sixth edition (TNM6), and seventh edition (TNM7) were compared on the basis of Akaike information criterion (AIC) and

APA, Harvard, Vancouver, ISO, and other styles

24

Vocka, Michal, Jan Spacek, Irena Netikova, et al. "Immunomonitoring in patients with stage II and III colon cancer." Journal of Clinical Oncology 35, no. 15_suppl (2017): e23038-e23038. http://dx.doi.org/10.1200/jco.2017.35.15_suppl.e23038.

Full text

Abstract:

e23038 Background: Colorectal cancer (CRC) is the second leading cause of cancer death worldwide. Immunoscore has been shown to be a very powerful prognositc indicator in patients with clinically localized colorectal cancer, with no detectable tumour spread to lymph nodes or distant organs. These patients are usually treated with only surgical removal of the tumour; however, approximately 25% of these patients will have recurrence of their disease, indicating that occult metastases were already present at the time of curative surgery. VEGF is the factor responsible for neoangiogenesis and it i

APA, Harvard, Vancouver, ISO, and other styles

25

Cohen, Romain, Qian Shi, and Thierry André. "Immunotherapy for Early Stage Colorectal Cancer: A Glance into the Future." Cancers 12, no. 7 (2020): 1990. http://dx.doi.org/10.3390/cancers12071990.

Full text

Abstract:

Immune checkpoint inhibitors (ICI) have reshaped therapeutic strategies for cancer patients. The development of ICI for early stage colorectal cancer is accompanied by specific challenges: (i) the selection of patients who are likely to benefit from these treatments, i.e., patients with tumors harboring predictive factors of efficacy of ICI, such as microsatellite instability and/or mismatch repair deficiency (MSI/dMMR), or other potential parameters (increased T cell infiltration using Immunoscore® or others, high tumor mutational burden, POLE mutation), (ii) the selection of patients at risk

APA, Harvard, Vancouver, ISO, and other styles

26

Shimura, T., Y. Okuda, T. Yamada, Y. Hirata, and T. Joh. "Colorectal obstruction is a potential prognostic factor for stage II/III colorectal cancer." Annals of Oncology 28 (November 2017): x50. http://dx.doi.org/10.1093/annonc/mdx659.028.

Full text

APA, Harvard, Vancouver, ISO, and other styles

27

Nepomnyashchaya, Evgeniya M., Elena P. Ulianova, Inna A. Novikova, et al. "ZEB1 expression in different stages of colorectal cancer." Journal of Clinical Oncology 39, no. 15_suppl (2021): e15526-e15526. http://dx.doi.org/10.1200/jco.2021.39.15_suppl.e15526.

Full text

Abstract:

e15526 Background: Colorectal cancer (CRC) is among the most common cancers. The leading cause of high mortality is tumor progression developed due to the epithelial to mesenchymal transition (EMT). The ZEB1 protein is one of the critical regulators of this process. In this regard, our study aimed to assess the ZEB1 expression in different stages of colorectal cancer. Methods: This study included samples of 206 patients with stage II-IV CRC aged 42 to 86 years (mean age 64.2±1.7). All patients were divided into three groups: group 1 - patients with T3-4 N0 M0 (stage II) with high-risk factors

APA, Harvard, Vancouver, ISO, and other styles

28

Vanhoefer, Udo, Andreas Harstrick, Wolf Achterrath, Shousong Cao, Siegfried Seeber, and Youcef M. Rustum. "Irinotecan in the Treatment of Colorectal Cancer: Clinical Overview." Journal of Clinical Oncology 19, no. 5 (2001): 1501–18. http://dx.doi.org/10.1200/jco.2001.19.5.1501.

Full text

Abstract:

PURPOSE AND METHODS: For more than three decades, the therapeutic options for patients with advanced colorectal cancer have almost exclusively been based on fluoropyrimidines. With the recognition that topoisomerase-I (TOP-I) is an important therapeutic target in cancer therapy, irinotecan, a semisynthetic TOP-I–interactive camptothecin derivative, has been clinically established in the treatment of colorectal cancer. RESULTS: Irinotecan was investigated as second-line chemotherapy after prior treatment with fluorouracil (FU)-based regimens in two large randomized phase III trials comparing ir

APA, Harvard, Vancouver, ISO, and other styles

29

Sasaki, Kazuaki, Keisuke Oono, Ai Konno, et al. "Adjuvant Chemotherapy for Stage II and III Colorectal Cancer." Nippon Daicho Komonbyo Gakkai Zasshi 67, no. 10 (2014): 869–76. http://dx.doi.org/10.3862/jcoloproctology.67.869.

Full text

APA, Harvard, Vancouver, ISO, and other styles

30

&NA;. "Fluorouracil + folinic acid promising in stage III colorectal cancer." Inpharma Weekly &NA;, no. 1290 (2001): 12. http://dx.doi.org/10.2165/00128413-200112900-00026.

Full text

APA, Harvard, Vancouver, ISO, and other styles

31

Massucci, M., A. Francesca, M. Veronica, et al. "Radically resected stage III colorectal cancer: sidedness and prognosis." Annals of Oncology 28 (October 2017): vi11. http://dx.doi.org/10.1093/annonc/mdx422.025.

Full text

APA, Harvard, Vancouver, ISO, and other styles

32

McCleary, Nadine Jackson, Al B. Benson, and Rodrigo Dienstmann. "Personalizing Adjuvant Therapy for Stage II/III Colorectal Cancer." American Society of Clinical Oncology Educational Book 37 (2017): 232–45. http://dx.doi.org/10.14694/edbk_175660.

Full text

APA, Harvard, Vancouver, ISO, and other styles

33

de Gramont, Aimery, Christophe Tournigand, Thierry André, Annette K. Larsen, and Christophe Louvet. "Adjuvant Therapy for Stage II and III Colorectal Cancer." Seminars in Oncology 34 (April 2007): S37—S40. http://dx.doi.org/10.1053/j.seminoncol.2007.01.004.

Full text

APA, Harvard, Vancouver, ISO, and other styles

34

Park, Min Young, In Ja Park, Hyo Seon Ryu, et al. "Optimal postoperative surveillance strategies for stage III colorectal cancer." World Journal of Gastrointestinal Surgery 13, no. 9 (2021): 1012–24. http://dx.doi.org/10.4240/wjgs.v13.i9.1012.

Full text

APA, Harvard, Vancouver, ISO, and other styles

35

Lee, K. "High Level of ASXL1 Protein Is Associated With Better Disease-Free Survival in Colorectal Cancer." Journal of Global Oncology 4, Supplement 2 (2018): 200s. http://dx.doi.org/10.1200/jgo.18.80800.

Full text

Abstract:

Background: ASXL1 gene is on chromosome region 20q11.21. Either amplification in cervical cancer or truncation mutations in colorectal cancers with microsatellite instability (MSI), malignant myeloid diseases, chronic lymphocytic leukemia, liver, prostate and breast cancers occurred. The functional and the prognostic roles of ASXL1 mutations and the expression of protein in colorectal cancer are still unknown. Aim: The aim of this study is to investigate the functional roles of ASXL1 mutations and the expression of protein in colorectal cancer. Methods: We performed NGS of 10 colorectal cancer

APA, Harvard, Vancouver, ISO, and other styles

36

Merkel, Susanne, Ulrich Mansmann, Thomas Papadopoulos, Christian Wittekind, Werner Hohenberger, and Paul Hermanek. "The prognostic inhomogeneity of colorectal carcinomas Stage III." Cancer 92, no. 11 (2001): 2754–59. http://dx.doi.org/10.1002/1097-0142(20011201)92:11<2754::aid-cncr10083>3.0.co;2-4.

Full text

APA, Harvard, Vancouver, ISO, and other styles

37

Park, James Hugh, Anniken Jorlo Fuglestad, Anne Helene Kostner, et al. "Systemic inflammation, adjuvant chemotherapy, and survival in stage III colorectal cancer: Results from the ScotScan Colorectal Cancer Collaborative." Journal of Clinical Oncology 38, no. 4_suppl (2020): 228. http://dx.doi.org/10.1200/jco.2020.38.4_suppl.228.

Full text

Abstract:

228 Background: The systemic inflammatory response (SIR) is a poor prognostic marker in patients with colorectal cancer (CRC), and predicts poor outcome following adjuvant chemotherapy. Whether this may be influenced by chemotherapy regime is not known. The present study examined the relationship between the pre-operative SIR, adjuvant therapy regime, and survival of patients with stage III CRC in the ScotScan cohort. Methods: Patients with stage III CRC in Scotland (1997-2015, n= 317) and Norway (2000-17, n= 312) were included. The pre-operative SIR was measured using C-reactive protein (CRP≤

APA, Harvard, Vancouver, ISO, and other styles

38

Shabunin, A. V., and Z. A. Bagateliya. "ALGORITHM OF SURGICAL CARE IN COMPLICATED COLORECTAL CANCER." Koloproktologia 18, no. 1 (2019): 66–73. http://dx.doi.org/10.33878/2073-7556-2019-18-1-66-73.

Full text

Abstract:

AIM: to standardize surgical care for the malignant colonic obstruction. PATIENTS AND METHODS: the retrospective cohort study included 797 patients with complicated colorectal cancer. Malignant colonic obstruction was diagnosed in 572 patients: 247 of them were treated in 2011-2013 (I group); 325 - in 2014-2017 (II). Urgent bowel resection was performed more often in I group (one-stage treatment), fecal diversion or stent- in II (two-stage treatment). Seventy-seven patients with tumor bleeding were included as well: 62 of them were treated conservatively or underwent endoscopic coagulation or

APA, Harvard, Vancouver, ISO, and other styles

39

Hommes, Saar, Ruben Vromans, Felix Clouth, Xander Verbeek, Ignace de Hingh, and Emiel Krahmer. "Communication in decision aids for stage I–III colorectal cancer patients: a systematic review." BMJ Open 11, no. 4 (2021): e044472. http://dx.doi.org/10.1136/bmjopen-2020-044472.

Full text

Abstract:

ObjectivesTo assess the communicative quality of colorectal cancer patient decision aids (DAs) about treatment options, the current systematic review was conducted.DesignSystematic review.Data sourcesDAs (published between 2006 and 2019) were identified through academic literature (MEDLINE, Embase, CINAHL, Cochrane Library and PsycINFO) and online sources.Eligibility criteriaDAs were only included if they supported the decision-making process of patients with colon, rectal or colorectal cancer in stages I–III.Data extraction and synthesisAfter the search strategy was adapted from similar syste

APA, Harvard, Vancouver, ISO, and other styles

40

Saraste, D., A. Martling, PJ Nilsson, J. Blom, S. Törnberg, and M. Janson. "Screening vs. non-screening detected colorectal cancer: Differences in pre-therapeutic work up and treatment." Journal of Medical Screening 24, no. 2 (2016): 69–74. http://dx.doi.org/10.1177/0969141316656216.

Full text

Abstract:

Objectives To compare preoperative staging, multidisciplinary team-assessment, and treatment in patients with screening detected and non-screening detected colorectal cancer. Methods Data on patient and tumour characteristics, staging, multidisciplinary team-assessment and treatment in patients with screening and non-screening detected colorectal cancer from 2008 to 2012 were collected from the Stockholm–Gotland screening register and the Swedish Colorectal Cancer Registry. Results The screening group had a higher proportion of stage I disease (41 vs. 15%; p < 0.001), a more complete stagin

APA, Harvard, Vancouver, ISO, and other styles

41

Wong, Anthony C., Shannon Stock, Deborah Schrag, et al. "Physicians' Beliefs About the Benefits and Risks of Adjuvant Therapies for Stage II and Stage III Colorectal Cancer." Journal of Oncology Practice 10, no. 5 (2014): e360-e367. http://dx.doi.org/10.1200/jop.2013.001309.

Full text

Abstract:

Physicians agreed that the benefits of adjuvant chemotherapy for stage III colon cancer and chemotherapy, and radiation for stage III rectal cancer, outweigh the risks, but were divided over the net benefit of adjuvant therapies for stage II colorectal cancer.

APA, Harvard, Vancouver, ISO, and other styles

42

Abi Jaoude, Joseph, Ramez Kouzy, Walker Mainwaring, et al. "The landscape of gastrointestinal oncologic phase III clinical trials in the last two decades." Journal of Clinical Oncology 38, no. 15_suppl (2020): e14087-e14087. http://dx.doi.org/10.1200/jco.2020.38.15_suppl.e14087.

Full text

Abstract:

e14087 Background: Gastrointestinal (GI) cancers are among the most common cancers in adult patients. The prognosis of GI cancers differs widely between specific subsites, with some cancers having excellent prognoses, and others (such as pancreatic and hepatobiliary cancers) having an extremely poor prognosis. We sought to characterize the landscape of GI oncologic clinical trials in the last two decades. Methods: We searched ClinicalTrials.gov for phase III RCTs between 2003 and 2018. Randomized multi-arm trials assessing a therapeutic intervention in adult cancer patients were included. GI c

APA, Harvard, Vancouver, ISO, and other styles

43

Wong, Melisa L., Timothy L. McMurry, Jessica R. Schumacher, et al. "Comorbidity Assessment in the National Cancer Database for Patients With Surgically Resected Breast, Colorectal, or Lung Cancer (AFT-01, -02, -03)." Journal of Oncology Practice 14, no. 10 (2018): e631-e643. http://dx.doi.org/10.1200/jop.18.00175.

Full text

Abstract:

Purpose: Accurate comorbidity measurement is critical for cancer research. We evaluated comorbidity assessment in the National Cancer Database (NCDB), which uses a code-based Charlson-Deyo Comorbidity Index (CCI), and compared its prognostic performance with a chart-based CCI and individual comorbidities in a national sample of patients with breast, colorectal, or lung cancer. Patients and Methods: Through an NCDB Special Study, cancer registrars re-abstracted perioperative comorbidities for 11,243 patients with stage II to III breast cancer, 10,880 with stage I to III colorectal cancer, and 9

APA, Harvard, Vancouver, ISO, and other styles

44

Jeon, Justin Y., Deok Hyun Jeong, Min Keun Park, Jennifer A. Ligibel, Jeffrey A. Meyerhardt, and Nam Kyu Kim. "Impact of diabetes on site-specific oncologic outcome in stage I-III colorectal cancer." Journal of Clinical Oncology 30, no. 15_suppl (2012): e14114-e14114. http://dx.doi.org/10.1200/jco.2012.30.15_suppl.e14114.

Full text

Abstract:

e14114 Background: Background: Conflicting results have been reported whether pre diagnosis diabetes mellitus (DM) influence survival of colorectal cancer patients or not. Therefore, we determine the influence of DM on long-term outcomes of stage 1-3 patients with resected colon and rectal cancer. Methods: This prospective study include a total of 4,131 participants who were treated for cancer between 1995 and 2005 in South Korea in a single hospital (Non DM: 3,614 patients, DM: 517 patients) with average follow up period of 12 years. We analyzed differences in all cause mortality, disease fre

APA, Harvard, Vancouver, ISO, and other styles

45

Sun, Yan Xia, Feng Wu Lin та Xue Mei Han. "Expression and Significance of Interleukin 1α mRNA in Colorectal Cancer". Advanced Materials Research 1033-1034 (жовтень 2014): 236–39. http://dx.doi.org/10.4028/www.scientific.net/amr.1033-1034.236.

Full text

Abstract:

Quantitative analysis for the relative mRNA expression of interleukin 1α (IL-1α) in colorectal cancer and cancer-adjacent tissues, the clinical significance of which will be investigated. Quantitative real-time polymerase chain reaction (qRT-PCR) was used to analyze the relative mRNA levels of IL-1α in 42 colorectal cancer tissues and corresponding cancer-adjacent tissues, statistically analyzing the co-relation of IL-1α mRNA levels with the differentiation, clinical stages and metastatic status of cancer. The relative content of IL-1α mRNA in colorectal tissues was 1.18 ± 0.80, and that in ca

APA, Harvard, Vancouver, ISO, and other styles

46

Berardi, Rossana, Tiziana Saladino, Davide Mari, et al. "Elderly Patients with Advanced Colorectal Cancer: Tolerability and Activity of Chemotherapy." Tumori Journal 91, no. 6 (2005): 463–66. http://dx.doi.org/10.1177/030089160509100603.

Full text

Abstract:

Aims and Background Colorectal cancer is the most common gastrointestinal tumor in Western countries and is increasing in elderly patients. In recent years, new treatments based on the use of 5-fluorouracil associated with oxaliplatin or CPT-11 have shown promising activity. The aim of the present study was to analyze the tolerability and activity of chemotherapy with 5-fluorouracil plus oxaliplatin or CPT-11 in elderly patients with advanced colorectal cancer. Methods Patients aged 70 years or older with advanced colorectal cancer were treated with 5-fluorouracil (400 mg/m2 in bolus and 600 m

APA, Harvard, Vancouver, ISO, and other styles

47

Ji, H., M. Zhang, K. Farnam, K. Salari, R. Davis, and J. M. Ford. "Analysis of genomic DNA copy number alterations in chromosome arm 18q demonstrates distinct molecular categories of colorectal carcinoma." Journal of Clinical Oncology 24, no. 18_suppl (2006): 10005. http://dx.doi.org/10.1200/jco.2006.24.18_suppl.10005.

Full text

Abstract:

10005 Background: Genomic instability is a major feature of neoplastic development in colorectal carcinoma and other cancers. Specific genomic instability events such as genomic deletions have potential utility as biologically relevant prognostic biomarkers. Loss of heterozygosity (LOH) on chromosome arm 18q is an indicator of colorectal carcinoma behavior and potentially, prognosis. For stage II and III colorectal cancer, a number of retrospective studies have shown strong correlations between deletions in 18q and reduced survival. However, other studies have failed to identify this correlati

APA, Harvard, Vancouver, ISO, and other styles

48

Guo, Tianhua, Marcin Krzystanek, Zoltan Szallasi, and Arpad Szallasi. "Thrombocytosis portends adverse prognostic significance in patients with stage II colorectal carcinoma." F1000Research 3 (July 31, 2014): 180. http://dx.doi.org/10.12688/f1000research.4856.1.

Full text

Abstract:

Thrombocytosis portends adverse prognostic significance in many types of cancers including ovarian and lung carcinoma. In this study, we determined the prevalence and prognostic significance of thrombocytosis (defined as platelet count in excess of 400 K/μl) in patients with colorectal cancer. We performed a retrospective analysis of 310 consecutive patients diagnosed at our institution between 2004 and 2013. The patients (48.7% male and 51.3% female) had a mean age of 69.9 years (+/- 12.7 years) at diagnosis. Thrombocytosis was found in a total of 25 patients, with a higher incidence in those

APA, Harvard, Vancouver, ISO, and other styles

49

Murphy, Caitlin C., Linda C. Harlan, Jennifer Leigh Lund, Charles Lynch, and Ann M. Geiger. "Patterns of colorectal cancer care in the United States: 1990-2010." Journal of Clinical Oncology 33, no. 3_suppl (2015): 684. http://dx.doi.org/10.1200/jco.2015.33.3_suppl.684.

Full text

Abstract:

684 Background: Colorectal cancer (CRC) incidence and mortality have declined in the U.S. over the past two decades. Much of the decline can be attributed to screening and advances in treatment. Few studies have evaluated the extent to which recommended therapies have been adopted in community settings and temporal changes in patterns of care. Methods: Patients diagnosed with stages II and III CRC were randomly sampled from the population-based Surveillance, Epidemiology, and End Results (SEER) program in 1990-91, 1995, 2000, 2005, and 2010 (n=7,056). Treatment data were obtained through medic

APA, Harvard, Vancouver, ISO, and other styles

50

Piga, A., M. Miscoria, G. Aprile, et al. "Treatment of colorectal cancer in elder patients." Journal of Clinical Oncology 25, no. 18_suppl (2007): 19595. http://dx.doi.org/10.1200/jco.2007.25.18_suppl.19595.

Full text

Abstract:

19595 Background: Tumor-related mortality is higher in elder patients worldwide. This may be due to comorbidities associated with age but also, at least in part, to a cautious approach by the attending physician(s) which might result in inadequate or even denied treatment. This approach is purportedly justified by scarcity of literature reports on effectiveness, tolerance and side effects of chemotherapy and other treatments on this category of patients. Methods: We have reviewed clinical records of patients of 70 years of age or older with colorectal cancer who came to our first observation b

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!